BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//chikkutakku.com//RDFCal 1.0//EN
X-WR-CALDESC:GoogleカレンダーやiCalendar形式情報を共有シェ
 アしましょう。近所のイベントから全国のイベントま
 で今日のイベント検索やスケジュールを決めるならち
 っくたっく
X-WR-CALNAME:ちっくたっく
X-WR-TIMEZONE:UTC
BEGIN:VEVENT
SUMMARY:基礎医学特論　TOKURON 
DTSTART;VALUE=DATE-TIME:20250627T090000Z
DTEND;VALUE=DATE-TIME:20250627T103000Z
UID:226675675617
DESCRIPTION:日時：令和7年6月27日（金）18:00〜19:50Date and Tim
 e: June 27\, 2025 (Fri)6:00 pm – 7:50 pm言語：英語Language: Engli
 sh場所：基礎研究棟会議室2（生協横）Venue: Meeting Room No
 .2\, Basic Medical Research Building (1st Floor)講演者 Speaker: Balvee
 n Kaur\, PhDTitle: oncolytic vital therapy for cancerAbstract:Identificati
 on of IDH mutations has uncovered the crucial roleplayed by metabolism in 
 gliomagenesis. Oncolytic herpes virus (oHSV) therapyinitiates direct tumor
  debulking by tumor lysis and activates antitumorimmunity\, however\, litt
 le is known about the role of glioma metabolism indetermining oHSV efficac
 y. Here we identify that oHSV rewires central carbonmetabolism increasing 
 glucose utilization towards oxidative phosphorylation andshuttling glutami
 ne towards reductive carboxylation in IDH wildtype (wt)glioma. The switch 
 in metabolism results in increased lipid synthesis and cellularROS. PKC in
 duces ACSL4 in oHSV treated cells leading to lipid peroxidation andferropt
 osis. Ferroptosis is critical to launch an antitumor immune responsewhich 
 is important for viral efficacy. Mutant IDH (IDHR132H) gliomas areincapabl
 e of reductive carboxylation and hence ferroptosis. Pharmacologicalblockad
 e of IDHR132H induced induces ferroptosis and antitumor immunity. Thisstud
 y provides a rationale to use an IDHR132H inhibitor to treat high gradeIDH
 -mutant glioma patients undergoing oHSV treatment.
LOCATION:
END:VEVENT
END:VCALENDAR